Objectives. Knee bone curvature assessed by MRI was associated with OA cartilage loss. A recent knee OA trial demonstrated the superiority of chondroitin sulfate over celecoxib (comparator) at reducing cartilage volume loss (CVL) in the medial compartment (condyle). The main objectives were to identify which baseline bone curvature regions of interest (BCROI) best associated with CVL and investigate whether baseline BCROI and 2-year change are correlated with the protective effect of chondroitin sulphate on CVL.
Introduction
OA is considered a disease of the whole joint, which includes the different tissues, such as cartilage, menisci, synovium and subchondral bone [1] . Subchondral bone shape and changes are recognized as important biomarkers because bone adapts to loads by remodelling to meet its mechanical demands, whereas subchondral bone changes, such as bone turnover, mineralization and volume, result in altered apparent and material density of bone that may adversely affect the joint's biomechanical environment [2] . The pathological changes in subchondral bone that occur in established knee OA include bone marrow lesions, osteophytes, alteration in bone shape, bone cysts and subchondral trabecular remodelling [3] .
One of the first and well-described changes in bone shape in knee OA is alterations of the bony surface contour under the denomination of bone attrition in MRI scoring systems [4] . However, its assessment remains highly subjective and hardly reproducible [5] , with inconsistent associations with knee structural progression [58] . In 2002, Hohe et al. [9] presented a new bone biomarker evaluated by MRI, named knee joint incongruity, which aimed to measure the compatibility between the curvature of the bone of the femur and tibia at their contact location. Benefiting from the knowledge of differential geometry, Bredbenner et al. [10] investigated the relationship between bone geometry and knee OA progression; the concept of bone curvature was then used as a novel biomarker of the condition of the bone in contact with cartilage. The usefulness of this biomarker was further explored in OA using different approaches [1116] . However, bone geometry has not yet been used as a biomarker in clinical trials, and thus whether bone curvature can be used to help predict the response to treatment in knee OA is unknown at this time. This could be of importance as data have already shown that changes in subchondral bone in knee OA could occur early during the disease process and be associated with greater cartilage volume loss (CVL). A recent Phase III clinical trial [17] has demonstrated that treatment with an anti-bone-remodelling drug, strontium ranelate, can protect against cartilage loss in patients with bone marrow lesions in the medial compartment.
The goal of this project was to evaluate, using the data from a 2-year randomized, controlled, double-blind clinical trial (MOSAIC) [18] , the effects of chondroitin sulphate vs celecoxib on bone curvature and its association with the extent of CVL in patients with symptomatic knee OA. The MOSAIC study showed a statistically significant reduction in CVL in the medial compartment (condyle) in the intention-to-treat population as well as in the accordingto-protocol (ATP) population in patients treated with chondroitin sulphate compared with celecoxib after both 12 and 24 months of treatment.
The aim of the present study was to provide unique data to explore and compare, in symptomatic knee OA patients, the effect of two treatments on bone curvature and to investigate the relationship between those findings and CVL. More specifically, the objectives of this study were to identify which bone curvature regions/subregions of interest (BCROI) at baseline best associated with CVL, investigate whether the BCROI (optimal regions/subregions) at baseline and change at 2 years could be correlated with the protective effect of chondroitin sulphate on CVL, and explore the sequence of events occurring between changes in bone curvature and CVL.
Methods

Patients
This post hoc study was conducted using the ATP population of a 2-year Phase III comparative, doubleblind, controlled trial (ClinicalTrials.gov Identifier NCT01354145). Patients with symptomatic knee OA and clinical synovitis were randomized to explore the effects of chondroitin sulphate (Condrosan 1200 mg daily; n = 97) compared with celecoxib (200 mg daily; n = 97), the comparator, on knee OA CVL [18] . Ethical approval for this post hoc study was obtained with the original study, thus further approval was not required, and all patients provided informed consent (for details, refer to the Patients section of the supplementary data, available at Rheumatology Online). In this study, we chose the ATP population as it included patients who fully complied with the study's 2-year protocol and for whom all MRI evaluations were available. No differences were found in baseline characteristics between the ATP (chondroitin sulphate n = 57; celecoxib n = 63) and randomized populations (data not shown).
Knee MRI acquisitions
MRI at baseline and 24 months was done as described [18] , on 1.5 T scanners (Siemens, Erlangen, Germany and General Electric, Milwaukee, WI, USA) using a standard knee coil. The sequence acquisitions were as previously described [19] . The reproducibility of the method has previously been demonstrated to be excellent [20] . The cartilage volume was measured as previously described [20, 21] .
Knee bone curvature
Bone curvature was calculated using the method described by Hohe et al. [9] adapted to the representation of the bone surface resulting from our automatic bone segmentation technology [22] . For details, refer to the Patients and Methods section of the supplementary data, available at Rheumatology Online.
To determine the optimal regions or combination of subregions for the bone curvature that best separates and maximizes the CVL progression, a global optimum search using systematic calculation of the correlation between CVL and bone curvature over all possible region combinations was performed. This procedure is similar to a published method [6] with regard to determining the most informative bone region to identify an OA progressor.
The MOSAIC study [18] demonstrated that the medial condyle was the best region to discriminate the difference in CVL between chondroitin sulphate and celecoxib groups; hence, this cartilage region was used to launch the search algorithm. Moreover, as celecoxib, the comparator, was previously demonstrated in a trial using MRI to have a non-different effect on the progression of CVL in knee OA patients compared with a historical control cohort [23] , it was chosen for the reference group to determine the optimal region or combination of regions of the bone area that would be the most informative to identify OA progressors.
Other measurements
The other measurements were as described in the MOSAIC trial [18] and included the synovial membrane thickness [24] , bone marrow lesion score [25] , SF volume [26] , meniscal extrusion [25, 27] , clinical joint effusion and swelling, visual analog scale pain and the WOMAC.
Statistical analysis
Data were entered into a computerized database using a blinded double-entry procedure, after which descriptive statistics for patient characteristics were tabulated. The determination of optimal combination of bone regions was based on the best Pearson's correlation of the bone curvature change and CVL (both expressed as percentages) in the medial condyle for the celecoxib (reference) group. A posteriori analysis was also done on the bone region combination showing a statistical significance (P < 0.05) for the bone curvature between baseline and its 2-year change, and contrasted between treatment groups using Student's t-test or MannWhitney U-test.
To assess whether the baseline bone curvature and change at 2 years in the BCROI (medial posterior and lateral central condyle) predicted the protective effect of chondroitin sulphate over celecoxib on the cartilage change at 2 years, we carried out univariate analysis (Student's t-test or KruskalWallis test) and multivariate analysis using analysis of covariance (ANCOVA), in which the confounding factors BMI and cartilage volume at baseline were used. Other tests were the 2 
test or
Fisher's exact test for categorical variables.
Correlation between CVL within the medial condyle and the BCROI over both 1 and 2 years was also assessed in a criss-cross manner using Pearson's correlation as an attempt to establish a sequence of events occurrence.
Statistical tests were two sided and significance was reached at P < 0.05 not correcting for multiple comparisons. Statistical analyses were performed using SAS Õ software version 9.3 (SAS Institute, Cary, NC, USA).
Results
The optimal region combination of bone curvature predictive of OA progressors is the medial posterior condyle and lateral central condyle Correlation analysis between the changes in bone curvature and the CVL in the medial condyle at 2 years (Table 1) revealed several combined regions reaching significance, the greatest being the combined medial posterior condyle and lateral central condyle (r = 0.33, P = 0.008; Table 1 and supplementary Fig. S1 , available at Rheumatology Online). All other region combinations of bone curvature changes yielded inferior correlations. Of note is the incidence of bone regions selected by the search algorithm while processing and finding the optimal combination (Table 1) , clearly showing the lateral central condyle (n = 18) and, to a lesser extent, the lateral central plateau (n = 12) and the medial posterior condyle (n = 11) bone regions as the prime areas selected repetitively, among many possibilities, to yield the best correlations.
As a further demonstration of the relevance of selecting the lateral central condyle and the medial posterior condyle as the BCROI, Table 1 also shows a posteriori data on the separability of bone curvature change over 2 years between treatment groups based on the corresponding bone region combination. For the BCROI, such separability was also found to be the best and the only one statistically different (P = 0.029) between the two treatment groups, in which the celecoxib group demonstrated a higher negative change (À6.1± 6.7% ), reflecting a greater bone flattening than the chondroitin sulphate group (À3.5 ± 6.5%).
Baseline bone curvature in the medial subregions and the BCROI values were similar between the two treatment groups
To verify the quality of the randomization (Table 2) , the knee bone curvature was measured in the medial subregions at baseline, comparing chondroitin sulphate with celecoxib. Data showed virtually identical values between treatment groups in any knee bone medial compartment and its subregions, including the BCROI, indicating excellent randomization.
BCROI discriminates the protective effect of chondroitin sulphate on CVL
We also compared the responsiveness of this marker with the treatment response by looking at the impact of chondroitin sulphate over celecoxib on CVL at 2 years and BCROI at baseline as well as the change at 2 years and the relationship between them.
As bone curvature is a fairly new outcome variable, we elected to use the median BCROI value at baseline and change at 2 years. Interestingly, the median baseline value of the BCROI in the medial condyle of this study's OA patients (35.5 m À1 ) was similar to the mean value reported by Hohe et al. [9] in healthy individuals (35.6 m À1 ; also refer to supplementary data, section Patients and Methods, available at Rheumatology Online). Thus, values lower than the median indicate greater flattening of the bone. Likewise, we also chose to stratify patients according to the median value of change in BCROI at 2 years to explore relevant associations with CVL at 2 years. In this instance, change higher than the median (more than the median; À4.4%) indicates increased disease severity (bone flattening).
We looked at the patient characteristics according to the abovementioned stratification and compared the treatment groups (Table 3 ). All the demographic values, except BMI for patients with bone curvature value above the median and cartilage volume at baseline for patients with bone curvature value lower than the median, were similar between the two treatment groups. Therefore, both were included as confounding factors in the multivariate analyses.
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Baseline BCROI
The percentage of CVL in the medial compartment and subregions was lower in the chondroitin sulphate than the celecoxib group (Table 4) . Statistical significance was reached for the medial compartment (P = 0.037, ANCOVA), and a trend toward significance for the medial condyle (P = 0.061) and central condyle (P = 0.057), only among patients who had bone curvature lower than the median at baseline. The effect size measured using the regression coefficient b was between 2.00 and 3.51. Such separability was not found for the patients with BCROI values higher than the median (35.5 m À1 ) at baseline (Table 4) . Moreover, no difference was seen in the lateral compartment/subregions (data not shown). These data indicate that in patients with more bone flattening at baseline in the BCROI, chondroitin sulphate had www.rheumatology.oxfordjournals.org a protective effect over celecoxib on the CVL in the medial compartment.
Although the relatively small sample size of this exploratory study and its post hoc design limited the number of variables to be added to the multivariate model analysis as it would adversely affect its statistical power, we nonetheless performed further analyses that included the two additional variables bone marrow lesion size and synovial membrane thickness, which, although not statistically significant between the treatment groups at baseline (Table 3) , could be of importance as they were previously shown to be reduced by chondroitin sulphate treatment [18, 28] . Those analyses showed a slight loss of statistical significance, but the overall conclusion about BCROI predicting power remained the same (supplementary Table S1 , available at Rheumatology Online).
Change at 2 years in the BCROI
Similar to the baseline values, the percentage of CVL in the medial compartment and subregions was lower in the chondroitin sulphate vs celecoxib group in patients who had a bone curvature value change more than the median (À4.4%; Table 5 ). Statistical significance was reached for the medial compartment (P = 0.011), condyle (P = 0.021) and central plateau (P = 0.030), with numerical trends for the medial plateau and central condyle. The effect size was between 2.11 and 3.43. As above, results from supplementary analysis done by adding bone marrow lesions and synovial membrane thickness were similar for both the P and b values (supplementary Table S2 , available at Rheumatology Online). Such separability was not demonstrated for the patients with less than median change in the BCROI (Table 5) , or in the lateral compartment (data not shown).
Change in BCROI at 1 year precedes change in CVL at 2 years We also explored, for the entire cohort (n = 120), the sequence of events between the change in the BCROI and the CVL in the medial condyle. To this end, changes at 1 and 2 years were contrasted in a criss-cross fashion (Table 6 ). Data indicated that change in the BCROI (flattening of the bone) at 1 year was associated with CVL at 2 years (r = 0.21, P = 0.019). However, the opposite did not show an association; the cartilage volume change at 1 year was not associated with greater change in BCROI at 2 years (Pearson's r = 0.10, P = 0.273).
Discussion
This post hoc study demonstrated, for the first time, the feasibility and usefulness of assessing bone curvature and its changes over time to explore the effectiveness of an OA treatment on structural changes, thus identifying bone curvature as a novel biomarker for clinical trials in knee OA. Indeed, in this clinical trial, the protective effect of chondroitin sulphate vs celecoxib on the CVL in patients with more severe changes in the bone curvature suggests this structure as a potential new biomarker to discriminate the efficacy of an OA treatment. In addition, this work suggests that a greater increase in the bone curvature changes precedes CVL, alluding to the predominant role of such changes in the progression of CVL.
The MOSAIC trial [18] demonstrated in knee OA patients that a 2-year treatment with chondroitin sulphate (1200 mg/day) had a significant beneficial effect vs celecoxib (200 mg/day) on CVL in the medial compartment associated with the medial condyle. Here, we showed that this treatment effect on CVL was associated with the alteration in the BCROI. This novel research finding has several important implications. First, it is well demonstrated that knee bone curvature, in general, flattens over time among patients with progressive knee OA, agreeing with data in the literature [11, 16] . This probably reflects compressing forces that the knee must sustain as the cartilage wears and thins over time, to which bone must adapt. Therefore, selecting patients with flattening of bone curvature may serve as a surrogate marker to identify patients at greater risk of disease progression, hence a greater chance to detect the therapeutic effect of a disease-modifying OA drug. These results demonstrate the potential of patient selection, based on baseline bone curvature, to improve the demonstration of any therapeutic effect.
The baseline regional bone curvatures were different among several areas of the medial compartment of the knee, yet no differences were observed between the treatment groups (Table 2) , suggesting some consistency of these curvatures on average among patients. The search algorithm systematically explored several possibilities of baseline bone curvature deformities, among which two subregions non-contiguous with the medial condyle cartilage were identified as the best candidates to predict subsequent CVL. The medial posterior condyle and the lateral central condyle were repeatedly selected by the search algorithm as the best possible bone regions associated with medial condyle CVL. The finding of the condyle over the plateau is consistent with prior literature reporting that more pronounced bone changes during OA occur in the condyle rather than in the plateau [9, 15] . Moreover, and interestingly, the two subregions selected by the algorithm are also in line with the data of Bredbenner et al. [10] , who, by using principal component analysis and a statistical shape model, demonstrated more variance for the medial posterior condyle and central lateral condyle. This introduces a potential of more significant change in the bone geometry in these regions, among which the curvature is a relevant indicator.
In addition, the medial posterior condyle is not the bone area most contiguous with the medial condyle cartilage, whereas the lateral central condyle is simply not in the same knee compartment (Table 1 and supplementary  Fig. S1 , available at Rheumatology Online). This disconnection between bone deformities and CVL may reflect compressing or shearing forces through the knee that may not be linear. The lateral compartment being an important component of the medial condyle CVL could be explained by the works of Ateshian et al. [29] and Hohe et al. [9] , who showed that when joint stress shifts from the medial to lateral compartment because of an excessive degree of OA, there is a rapid change in the lateral condyle bone shape and curvature attributable to the high level of incongruity of the lateral tibiofemoral joint. Moreover, it has also been suggested that cartilage thinning, meniscal lesions and ligament loosening or even damage may all The region of interest included the medial posterior condyle and lateral central condyle.
www.rheumatology.oxfordjournals.org contribute to knee instability and criss-cross force patterns. Such knee instability may translate into knee structural change locations for bone and cartilage as reported [9, 29] . The selection by the search algorithm of the two bone subregions (BCROI), that is the combination of the medial posterior condyle and the lateral central condyle, surpassing any isolated bony region in predicting medial compartment CVL, may provide further explanation for this criss-cross knee instability hypothesis.
When applying the a priori selection of the BCROI flattening, as determined by the algorithm, the therapeutic difference in CVL between chondroitin sulphate and celecoxib was reinforced by virtue of selection of patients with the greater baseline BCROI flattening. These results reveal the potential of patient selection based on baseline bone curvature to improve the demonstration of any therapeutic effect. Moreover, the measurement of such bone curvature change over time may also be useful for identifying patients who may respond better to therapy, as those patients with more rapid flattening at 2 years were also associated with even more significant protection by chondroitin sulphate vs celecoxib against CVL in the medial compartment.
The temporal sequence between bone curvature changes and CVL is extremely interesting. Our findings that the BCROI changes at 1 year were associated with a 2-year medial CVL, whereas the 1-year medial condyle CVL was not associated with a 2-year bone curvature change, is a paramount finding of the present study. It clearly suggests that bone changes may precede CVL, hence providing an important clue to the chicken-or-egg question about the sequence of knee OA structural changes. This agrees with data reporting that changes in bone shape appeared very early during the OA disease process and predicted later radiographic OA [15, 30, 31] . In addition, regarding the BCROI subregions, Neogi et al. [15] demonstrated that the femur, among the other bone regions studied (tibia and patella), showed a higher predictive value for the development of incident radiographic knee OA.
As with all studies, the present study has limitations. The relatively small sample size of this exploratory study and its post hoc design precluded statistical correction for the multiple comparisons and limited the number of variables to be added to the multivariate model analysis. However, we performed supplementary statistical determinations by adding to the model, in addition to the factors that were different at baseline between the treatment groups, two other factors on which chondroitin sulphate had a positive effect. Data showed that the BCROI predicting power remained the same. Moreover, the identification of the BCROI was based on the MOSAIC trial results, and post hoc identification of such subregions may prove not to be the same for a different OA patient population. It is likely that such BCROI determination in another population could be different from the two subregions selected, implying that BCROI may not be the same in other trial settings to predict CVL. For instance, differences between patients in OA disease duration, which intuitively may impact bone curvature, are never really known because the onset of knee pain probably does not reflect the true origin time point of the structural degradation. Moreover, the ultimate knee OA causality (microtrauma, heredity or metabolic factors and other unknown factors) may prove to be different from one patient to another, and such causal heterogeneity may in turn impact different optimal bone curvature selections by the search algorithm. The site of action of the treatment could also vary as represented by different trials assessing disease-modifying OA drugs using MRI, in which the effectiveness was found in the lateral compartment [28, 32, 33] . This could be explained by many factors, including the differences in disease severity between patients in a given study. This has been reported in previous studies and, more specifically, where the combination of chondroitin sulphate plus glucosamine was studied [34, 35] . These agents demonstrated a protective effect in the medial subregions in knee OA subjects with less severe disease but in the lateral compartment in patients experiencing more severe structural disease. Additionally, it is not known whether agents specifically targeting bone may imply the selection of different bone regions to optimize the identification of optimal protection against CVL. Finally, the determination by virtue of the median values of both the baseline curvature (35.5 m À1 ) and change in curvature over time (À4.4%) to separate treatment impact on CVL in our patient cohort may not be generalizable, although the baseline median value was similar to that found for the mean of healthy subjects in the medial condyle [9] .
In conclusion, the study showed that an optimal bone curvature region may help with better identification of patients who are at greater risk for disease progression; the assessment of knee bone curvature and its change over time could be used as a new biomarker to assess the effectiveness of treatment on CVL. In addition, the present work identifies a possible new mode of action of chondroitin sulphate at reducing the long-term progression of knee OA structural changes. These findings may also eventually help in patient selection for clinical trials and may optimize long-term management of knee OA by personalizing interventions.
Supplementary data
Supplementary data are available at Rheumatology Online.
expenses that arose during the course of the original study (MOSAIC).
